APP下载

华蟾毒配基抑制组蛋白乙酰化诱导肝癌细胞死亡的机制

2018-09-17毕成徐瑞成邹爽王聪聪张妍徐忠伟

中国医药导报 2018年23期

毕成 徐瑞成 邹爽 王聪聪 张妍 徐忠伟

[摘要] 目的 探讨华蟾毒配基通过改变表观遗传修饰调控肝癌细胞死亡的机制。 方法 通过CCK-8法检测不同浓度(0、0.75、1.5、2.5、5、10 μmol/L)华蟾毒配基作用于肝癌HepG2细胞24 h细胞增殖能力的变化;5 μmol/L华蟾毒配基作用HepG2细胞12、24 h后,流式细胞术检测细胞周期,蛋白印迹检测钙/钙调素依赖蛋白激酶2β(CaMK2B)、甲基化CpG结合蛋白2(MeCP2)、磷酸化MeCP2(p-MeCP2)、乙酰化组蛋白H3.1(Ac-Histone3.1)和甲基化组蛋白(Met-Histone3.1)的表达变化;5 μmol/L华蟾毒配基作用HepG2细胞24 h后,细胞免疫荧光结合扫描共聚焦检测CaMK2B和MeCP2相互作用。 结果 华蟾毒配基能显著抑制肝癌HepG2细胞生长,抑制效果呈现浓度依赖性,差异有统计学意义(P < 0.05),药物作用细胞后,细胞周期发生G2/M期阻滞,差异有统计学意义(P < 0.05)。5 μmol/L華蟾毒配基可促进CaMK2B和MeCP2在细胞核内结合,Western blot 结果显示华蟾毒配基作用HepG2细胞后上调CaMK2B和p-MeCP2表达(P < 0.05),抑制Ac-Histone3.1表达,促进Met-Histone3.1(P < 0.05)。 结论 华蟾毒配基通过激活CaMK2B-MeCP2信号通路抑制组蛋白乙酰化、促进甲基化继而诱导肝癌细胞死亡。

[关键词] 华蟾毒配基;肝细胞癌;钙调蛋白激酶;表观遗传

[中图分类号] R735.7 [文献标识码] A [文章编号] 1673-7210(2018)08(b)-0004-05

[Abstract] Objective To investigate the mechanism of cinobufagin in regulating the death of liver cells by regulating epigenetic modification. Methods The CCK-8 assay was used to detect the changes of proliferation ability after different concentrations (0, 0.75, 1.5, 2.5, 5, 10 μmol/L) of cinobufagin acting on the HepG2 cells for 24 h; after 5 μmol/L of cinobufagin acting on the HepG2 cells for 12, 24 h, the cell cycle was detected by flow cytometry, and the expression levels of Ca2+/Calmodulin-dependent protein kinase 2β (CaMK2B), methylated-cpg binding protein (MeCP2), phosphorylation-MeCP2 (p-MeCP2), acetylated histone H3.1 (Ac-Histone3.1) and methylated histones (Met-Histone3.1) were detected by Western blot; after 5 μmol/L of cinobufagin acting on the HepG2 cells for 24 h, the interaction between CaMK2B and MeCP2 in HepG2 cells was detected by cell immunofluorescence combined with confocal scanning. Results Cinobufagin could inhibit the growth of HepG2 cells in a dose-independent manner, the difference was statistically significant (P < 0.05), after the drug acting on the cells, the cell cycle comes up G2/M phase arrest, the difference was statistically significant (P < 0.05). 5 μmol/L of cinobufagin could promote the incorporation of CaMK2B and MeCP2 in cell nucleus, the results of Western blot showed that the cinobufagin could increase the expression of CaMK2B and MeCP2 after acting on HepG2 cells (P < 0.05), inhibit the expression of the Ac-Histone3.1, and promote the Met-Histone3.1 (P < 0.05). Conclusion Cinobufagin can induce the death of liver cells by activating the CaMK2B-MeCP2 signal path, inhibiting histone acetylation and promoting histone methylation.

[Key words] Cinobufagin; Hepatocellular carcinoma; Calmodulin kinase; Epigenetic

蟾酥的主要成分是华蟾毒配基等,与植物來源的哇巴因和地高辛等均属于强心苷类固醇物质(cardiotonic steroids,CSs)[1-3]。CSs是钠钾ATP酶抑制因子,可以增加细胞内Na+浓度,间接促进细胞内Na+和细胞外Ca2+的交换,导致细胞内Ca2+浓度增加,增强心肌收缩力[4-5]。值得关注的是,国外20年的流行病学研究发现,激素敏感型癌症(宫颈癌和乳腺癌)患者术后服用强心苷类固醇药物地高辛拮抗化疗诱发的心力衰竭,能够使患者5年死亡率从34%显著降低至6%[6]。CSs也能激活Ca2+信号途径诱导肿瘤抑制基因(tumor suppressor genes,TSGs)重编程发挥抗癌作用[7]。我们前期研究结果显示,华蟾毒配基能够显著改变肝癌细胞DNA分子的拓扑结构,引起染色体重塑,参与基因转录表达的重新编程[8]。然而具体机制尚不明确,因此,我们推测华蟾毒配基可能通过改变肝癌细胞表观遗传发挥抗癌机制。……

登录APP查看全文